Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
SBNY Signature Bank
JAPSY Japan Airlines Co Ltd
BKEP Blueknight Energy Partners LP
CPN Calpine Corp
FDFT Foodfest International 2000 Inc
PRAH PRA Health Sciences Inc
ITGR Integer Holdings Corp
MLPI UBS ETRACS Alerian MLP Infrastructure Index ETN
SR Spire Inc
Go

Health Care : Biotechnology | Large Cap GrowthCompany profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Closing Price
$151.37
Day's Change
-1.35 (-0.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
153.26
Day's Low
150.31
Volume
(Below Average)
Volume:
913,411
10-day average volume:
1,130,827
913,411
  • Prev Close
    152.72
  • Today's Open
    152.79
  • Day's Range
    150.31-153.26
  • Avg Vol (10-day)
    1.1M
  • Last (time)
    4:00p ET 08/16/17
  • Last (size)
    3
  • 52-Wk Range
    71.46 - 167.86
    LowHigh
  • (12/22/16 - 07/25/17)
    9.82%
  • 42.0%
  • Market Cap
    38.2B
  • Shares Outstanding
    252.1M
  • 1.03
  • 149.53x
  • No dividend
  • Ex-dividend
    No dividend
  • 1.8
  • 96.62
  • (% of float 07/31/17)
    1.45

Latest News

Yesterday's News, August 16, 2017
9:39 am ET
MarketWatch
August 11, 2017
8:00 am ET
BusinessWire
August 08, 2017
6:56 am ET
MarketWatch
August 07, 2017
6:10 am ET
PR Newswire
August 01, 2017
8:01 am ET
BusinessWire
July 31, 2017
7:33 am ET
MarketWatch
July 26, 2017
4:01 pm ET
BusinessWire
July 25, 2017
4:01 pm ET
BusinessWire
7:00 am ET
Globe Newswire
July 24, 2017
9:18 am ET
Zacks
7:00 am ET
BusinessWire
July 19, 2017
9:57 am ET
MarketWatch
8:00 am ET
MarketWatch
6:52 am ET
MarketWatch
6:51 am ET
MarketWatch
6:20 am ET
MarketWatch
July 18, 2017
6:19 pm ET
MarketWatch
4:23 pm ET
MarketWatch
4:01 pm ET
BusinessWire
July 17, 2017
8:57 am ET
MarketWatch
8:45 am ET
BusinessWire
July 13, 2017
8:00 am ET
BusinessWire
4:00 am ET
BusinessWire
June 30, 2017
6:35 am ET
PR Newswire
June 22, 2017
12:00 pm ET
PR Newswire
June 20, 2017
12:25 pm ET
MarketWatch
June 09, 2017
8:30 am ET
BusinessWire
4:31 am ET
BusinessWire
June 08, 2017
4:15 pm ET
BusinessWire
June 01, 2017
1:15 pm ET
BusinessWire
May 26, 2017
6:59 am ET
MarketWatch
May 24, 2017
10:00 am ET
BusinessWire
May 22, 2017
7:00 am ET
BusinessWire
May 19, 2017
6:45 am ET
BusinessWire
May 17, 2017
4:18 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , , and

Copyright © 2017. All rights reserved.